1.. INTRODUCTION
================

Micro[rna]{.smallcaps}s (mi[rna]{.smallcaps}s) are natural non-coding [rna]{.smallcaps}s of approximately 22 nucleotides (nt) in size. They regulate genes post-transcriptionally by binding to a site in the 3′ untranslated region ([utr]{.smallcaps}) of target messenger [rna]{.smallcaps}s (m[rna]{.smallcaps}s). Identification of an mi[rna]{.smallcaps} target involves base pairing with the target site, which is mostly imperfect in the case of animals. However, a perfect pairing in a 7-nt region at the 5′ end of mi[rna]{.smallcaps}, called the seed region, is essential for target identification [@b1-conc17-1-70].

The mi[rna]{.smallcaps}s are known to regulate cellular processes such as stem-cell differentiation, heart development [@b2-conc17-1-70]--[@b4-conc17-1-70], insulin secretion [@b5-conc17-1-70], apoptosis [@b6-conc17-1-70],[@b7-conc17-1-70], aging [@b8-conc17-1-70],[@b9-conc17-1-70], and immunity [@b10-conc17-1-70],[@b11-conc17-1-70], among other processes. It is therefore not surprising that mi[rna]{.smallcaps}s are differentially expressed in several pathophysiologic conditions including, for instance, Alzheimer disease [@b12-conc17-1-70],[@b13-conc17-1-70], Parkinson disease [@b14-conc17-1-70], cardiovascular diseases [@b4-conc17-1-70],[@b15-conc17-1-70],[@b16-conc17-1-70], the Cowden and Down syndromes [@b17-conc17-1-70],[@b18-conc17-1-70], and various cancers [@b19-conc17-1-70].

Let-7 was first discovered and well studied in *Caenorhabditis elegans,* in which it regulates developmental timing [@b20-conc17-1-70]--[@b23-conc17-1-70] (larval stage 4--to--adult transition [@b20-conc17-1-70],[@b24-conc17-1-70]) and stage-specific neuromuscular tissue development [@b25-conc17-1-70]. Let-7 has orthologs in various species. In *Drosophila,* let-7 plays a role in determining the timing for cell-cycle exit, metamorphosis, neuromuscular Junction development, juvenile-to-adult-stage transition, and adult behaviour [@b26-conc17-1-70],[@b27-conc17-1-70]. The zebrafish ortholog of let-7 is prominently expressed in nervous tissue, indicating its certain role in neural development [@b28-conc17-1-70]. In the adult newt, let-7 regulates transdifferentiation and regeneration of lens and inner ear-hair cells [@b29-conc17-1-70].

Little is known about the function of let-7 in mammalian development and normal physiology. In the mouse, let-7 is involved in neural lineage specificity of embryonic stem cells, brain development [@b30-conc17-1-70], and mammary epithelial progenitor cell maintenance by induction of loss of self-renewal [@b31-conc17-1-70]. In humans, 12 genomic loci encode the let-7 family members (let-7a-1, -2, -3; let-7b; let-7c; let-7d; let-7e; let-7f-1, -2; let-7g; let-7i; [mir]{.smallcaps}98). Human let-7 is upregulated during embryonic cell differentiation [@b32-conc17-1-70], but the roles it plays in normal physiology are mostly unknown.

Human let-7 family members are found to be downregulated in several cancers, with a few exceptions ([Table I](#tI-conc17-1-70){ref-type="table"}); restoration of normal expression prevents tumorigenesis [@b37-conc17-1-70],[@b44-conc17-1-70],[@b45-conc17-1-70],[@b52-conc17-1-70]. Let-7 therefore acts as a tumour suppressor and a regulator of terminal differentiation and apoptosis. This finding implies that let-7 can possibly be used as a next-generation cancer therapeutic. But, to date, the mechanism of let-7 deregulation, and its precise role in tumorigenesis, is not fully understood, creating a hurdle to effectively using this mi[rna]{.smallcaps} in cancer therapy.

This article presents an overview of let-7 and discusses the critical issues that must be explored to develop a let-7--based therapeutic strategy against various cancers.

2.. DISCUSSION
==============

2.1. Biogenesis and Mechanism of Action
---------------------------------------

The biogenesis of let-7 is similar to that of other mi[rna]{.smallcaps}s. The first step in mi[rna]{.smallcaps} biogenesis is transcription from the mi[rna]{.smallcaps} transcription unit by [rna]{.smallcaps} polymerase [ii]{.smallcaps} to produce a primary transcript called pri-mi[rna]{.smallcaps}. The pri-mi[rna]{.smallcaps} is processed by the microprocessor complex containing an [rna]{.smallcaps}se [iii]{.smallcaps}--like enzyme, Drosha, and its cofactor, a double-stranded [rna]{.smallcaps} binding protein, Dgcr8, to produce an approximately 60--70 nt pre-mi[rna]{.smallcaps} (precursor mi[rna]{.smallcaps}). The pre-mi[rna]{.smallcaps} is then transported to cytoplasm by exportin 5 (*XPO5*), in a Ran[gtp]{.smallcaps} (*ras-*related nuclear protein--guanosine triphosphate complex)--dependent way, where it is cleaved by Dicer (a cytoplasmic [rn]{.smallcaps}ase [iii]{.smallcaps}), to generate an imperfect mi[rna]{.smallcaps}:mi[rna]{.smallcaps}\* duplex of approximately 21--24 nt. One of the strands (the "guide strand") from the duplex is then incorporated into Argonaute (Ago)--containing ribonucleoprotein ([rnp]{.smallcaps}) complex; the other strand (the "passenger strand") is degraded. However, there are cases in which both strands of the duplex are detected in the cell [@b53-conc17-1-70]. The mi[rna]{.smallcaps}--Ago [rnp]{.smallcaps} complex causes posttranscriptional regulation of genes, in which mi[rna]{.smallcaps} is used as a tether to guide the complex to the specific m[rna]{.smallcaps}. The exact mechanism by which the mi[rnp]{.smallcaps} complex regulates expression of the target remains unclear. Various models try to explain this mechanism [@b1-conc17-1-70]. [Figure 1](#f1-conc17-1-70){ref-type="fig"} shows a general model.

2.2. Regulation of Let-7
------------------------

Expression of let-7 is regulated at various stages of its biogenesis and also depending on cell type. Similarly, let-7 regulates many transcription factors that play important roles in regulation of the cell cycle, cell differentiation, and apoptosis. Many of the factors controlling the expression of let-7 form regulatory circuits with the factors being regulated by such expression. These regulatory circuits---such as double-negative feedback loops and so on---are salient network motifs in development and differentiation. *LIN28, POU5F1, SOX2, NANOG, TLX1, HMGA2, MYC,* and *IMP*s are known to form such regulatory loops ([Figure 2](#f2-conc17-1-70){ref-type="fig"}).

### 2.2.1. Regulation of Let-7 by Pluripotency-Promoting Factors in Embryonic and Cancer Stem Cells

*LIN28,* which maintains the undifferentiated state of embryonic cells, is a well-known target of let-7 and is downregulated by let-7 during developmental commitment [@b54-conc17-1-70],[@b55-conc17-1-70]. Lin28 was recently shown to act as a posttranscriptional repressor of let-7 biogenesis, binding to the loop portion of the pri--let-7 hairpin and the stem part of pre--let-7 and thereby inhibiting its processing. Lin28 and Lin28B also inhibit processing of let-7 by mediating terminal uridylation of let-7 precursors [@b56-conc17-1-70]. What is unclear is whether the regulation by Lin28 occurs at the Drosha or Dicer processing step [@b55-conc17-1-70],[@b57-conc17-1-70]--[@b59-conc17-1-70]. Lin28 induces pri--let-7 expression through induction of other pluripotency-promoting factors such as Pou5F1, Sox2, Nanog, and Tlx1 [@b60-conc17-1-70], thus regulating let-7 expression at multiple levels.

The early embryonic oncofetal gene *HMGA2* is involved in the self-renewal and maintenance of adult stem cells. It is highly expressed in hematopoietic and fetal neuronal stem cells [@b61-conc17-1-70],[@b62-conc17-1-70], and the low levels of let-7 in stem cells inversely correlate with *HMGA2* expression. Thus, the undifferentiated state is maintained [@b63-conc17-1-70]. In differentiated tissues, *HMGA2* is downregulated because of the high expression of let-7 [@b61-conc17-1-70], and during induced differentiation, ectopic expression of let-7 reduces *ras* and *HMGA2* expression, leading to inhibition of cell proliferation and induction of apoptosis. Therefore, *HMGA2* is a direct target of let-7 [@b64-conc17-1-70].

Like normal stem cells, cancer stem cells (slowly dividing tumour-initiating cells) exhibit low levels of let-7 and possess unlimited self-renewal capability and pluripotency, allowing them to repopulate and metastasize [@b65-conc17-1-70],[@b66-conc17-1-70]. It has been proposed that, during carcinogenesis, the let-7--targeted embryonic genes, which are otherwise not expressed in adult tissues, are re-expressed because of loss of let-7 control. This reprogramming promotes de-differentiation and cancer progression [@b67-conc17-1-70]. A good example is that of *HMGA2,* which is undetectable in most differentiated tissues, but highly expressed in various cancers, including neuroblastoma and pancreatic, lung, and thyroid cancers [@b68-conc17-1-70]--[@b71-conc17-1-70]. Breast cancer stem cells are also devoid of let-7, but abundantly express *HMGA2* and *ras* [@b36-conc17-1-70] ([Figure 2](#f2-conc17-1-70){ref-type="fig"}).

### 2.2.2. Regulatory Circuit Between Myc and Let-7

*IMP1* is another oncofetal gene that is expressed only during early fetal life [@b72-conc17-1-70],[@b73-conc17-1-70] and is re-expressed in several cancers [@b74-conc17-1-70]. It is selectively expressed in young, but not in old, hematopoietic stem cells [@b75-conc17-1-70]. *IMP1* regulates stem cell functions by stabilizing insulin-like growth factor 2 and C-*myc* m[rna]{.smallcaps}s [@b76-conc17-1-70],[@b77-conc17-1-70], and the phenotype of stem cells from the *IMP1* knockout mouse resembles that of cells from the *HMGA2-*deficient mouse [@b73-conc17-1-70],[@b78-conc17-1-70]. Let-7 targets *IMP1*, and therefore indirectly acts as a negative regulator of *MYC* expression [@b64-conc17-1-70],[@b79-conc17-1-70],[@b80-conc17-1-70]. It has been shown that Myc binds directly to let-7 promoter and downregulates its transcription [@b81-conc17-1-70]. Thus, an indirect feedback circuit exists between let-7 and Myc ([Figure 2](#f2-conc17-1-70){ref-type="fig"}).

2.3. Let-7 Targets Multiple Oncogenes and Components of Cell Cycle, Cell Proliferation, and Apoptosis
-----------------------------------------------------------------------------------------------------

Apart from targeting oncogenes (*ras, MYC, HMGA2*, and so on) as already discussed, let-7 regulates several key components of the cell cycle and cell proliferation. Microarray analysis of hepatocellular carcinoma (HepG2) and lung cancer (A549) cell lines revealed that let-7 inhibits multiple cell-cycle- and proliferation-associated genes, including cyclin A2 (*CCNA2*), *CDC34,* Aurora A \[*AURKA* (formerly *STK6*)\] and B \[*AURKB* (formerly *SKT12*)\] kinases, *E2F5, CDK8,* and *PLAGL2,* among others [@b46-conc17-1-70]. In HepG2 cells, let-7 directly represses *CCNA2, CDC25A, SKP2, AURKA, CDC16, CCND1,* and *CDK6,* among others. Let-7 also inhibits several [dna]{.smallcaps} replication machinery components (*ORC1L; RRM1, 2*; and so on) and transcription factors \[*E2F6, CBFB, PLAGL2, SOX9, GZF1* (formerly *ZNF336*), *YAP1, GTF2I, ARID3A,* and so on\]. Surprisingly, that study also showed that let-7 represses several tumour suppressor genes (*BRCA1, BRCA2, FANCD2,* and *PLAGL1,* among others) and checkpoint regulators (*CHEK1, BUB1, BUB1B, MAD2L1,* and *CDC23,* among others). Our recent *in silico* analysis shows that let-7 may potentially target [er]{.smallcaps} signalling and angiogenic pathways by targeting key molecules of these cascades [@b82-conc17-1-70]. Various targets of let-7 are listed in [Table II](#tII-conc17-1-70){ref-type="table"} and shown in [Figure 3](#f3-conc17-1-70){ref-type="fig"}.

Apoptosis regulatory functions of let-7 have recently been reported in both human and mouse. Let-7 targets Casp3 in the A431 and HepG2 cell lines, and inhibits doxorubicin- and paclitaxel-induced apoptosis [@b85-conc17-1-70]. In NIH3T3 mouse fibroblast cells, let-7 is involved in ultraviolet B--induced apoptosis by modulating Casp3, Bcl2, Map3k1, and Cdk5 [@b86-conc17-1-70].

2.4. Emerging Role of Let-7 in Cancer Diagnosis and Therapy
-----------------------------------------------------------

The facts discussed here indicate that let-7 acts as a tumour suppressor by targeting various oncogenes and key components of the cell cycle and developmental pathways. Most reports reveal that let-7 is frequently underexpressed ([Table I](#tI-conc17-1-70){ref-type="table"}) and that the chromosomal region of human let-7 is frequently deleted in many cancers [@b87-conc17-1-70]. Similarly, in more differentiated tumour cells, let-7 is expressed at higher levels, and its target oncogenes (*HMGA2* and *ras*) are downregulated. Thus, loss of let-7 expression is a marker for less differentiated cancer [@b88-conc17-1-70], and expression levels are also found to be effective prognostic markers in several cancers [@b40-conc17-1-70],[@b46-conc17-1-70],[@b88-conc17-1-70]. In lung cancer, reduced let-7 expression was also found to significantly correlate with shortened postoperative survival regardless of disease stage [@b45-conc17-1-70].

From the therapeutic viewpoint, let-7 is attractive molecule for preventing tumorigenesis and angiogenesis [@b89-conc17-1-70]; it is a potential therapeutic in several cancers that underexpress let-7. Let-7 replacement was found to inhibit anchorage-independent growth and cell-cycle progression in melanoma cells by repressing regulators of the cell cycle and cell proliferation such as cyclins A, D1, and D3 and *CDK4* [@b47-conc17-1-70]. Together with *TP53, ras* and *MYC* have been implicated as key oncogenes in lung cancer. The reduced expression of let-7 in lung cancer directly correlates with upregulation of oncogene *ras*; introduction of let-7 represses *ras* and *MYC* translation by targeting the related m[rna]{.smallcaps}s [@b45-conc17-1-70],[@b46-conc17-1-70]. In both lung and hepatocellular carcinomas, replacement or restoration of normal expression levels of let-7 inhibits cancer growth by repressing multiple cell-cycle and proliferation pathways, together with *ras* and *MYC* [@b37-conc17-1-70],[@b44-conc17-1-70],[@b45-conc17-1-70],[@b52-conc17-1-70] ([Table II](#tII-conc17-1-70){ref-type="table"}). Intranasal let-7 administration was found effective in reducing tumour growth in a K-*ras* mutant mouse model of lung cancer [@b90-conc17-1-70]. Similarly, restoration of let-7 restrains the growth and proliferation of colon and hepatic cancers [@b40-conc17-1-70],[@b80-conc17-1-70]. Transfection of let-7 in a Burkitt lymphoma cell line downregulates *MYC* and reverts *MYC-*induced cell growth [@b38-conc17-1-70]. Ectopic expression of let-7 inhibits cell proliferation by directly repressing the *HMGA2* oncogene in lung cancers [@b52-conc17-1-70],[@b83-conc17-1-70] and uterine leiomyoma [@b84-conc17-1-70].

Induced expression of let-7 in breast cancer cells targets *HMGA2* and H-*ras* [@b36-conc17-1-70], and in a mouse model of breast cancer, exogenous let-7 delivery suppresses cell proliferation, mammosphere formation, and the population of undifferentiated cells by downregulating both of the foregoing oncogenes [@b35-conc17-1-70],[@b36-conc17-1-70]. In our *in silico* analysis, we recently showed that, apart from repressing *MYC, ras,* and *HMGA2,* let-7 may also target *CYP19A1, ESR1,* and *ESR2,* thereby potentially blocking estrogen signalling in [er]{.smallcaps}-positive breast cancers. Similarly, by repressing angiogenin, fibroblast growth factor, transforming growth factor, interleukin 6, and matrix metallopeptidase 2, let-7 may prevent growth, angiogenesis, and metastasis in breast cancer [@b82-conc17-1-70] ([Table II](#tII-conc17-1-70){ref-type="table"}).

2.5. Limitations of Let-7--Based Therapy
----------------------------------------

### 2.5.1. Limitations Because of Limited Knowledge of Let-7 Biology

Although restoration of normal let-7 expression proves beneficial, limited knowledge concerning its transcriptional and processing control during biogenesis and its exact role in tumorigenesis make it difficult to directly apply let-7 as a therapeutic. It is necessary to know whether downregulation of let-7 in tumours is a primary or secondary phenomenon during tumorigenesis. Supporting the [csc]{.smallcaps} hypothesis, we agree with the opinion that epigenetic downregulation of let-7 in [csc]{.smallcaps}s leads to upregulation of oncofetal genes (*HMGA2* and *LIN28,* among others) and, thereby, to loss of differentiation and tumorigenesis. In that scenario, downregulation of let-7 is the primary event, a view that can be supported by observation of where in ovarian cancer let-7 is hypermethylated [@b48-conc17-1-70].

Because mi[rna]{.smallcaps}s act on the 3′ [utr]{.smallcaps} of target m[rna]{.smallcaps}s, it is important to determine how efficiently let-7 will work as a therapeutic, because 3′ [utr]{.smallcaps} truncated oncogenes may be prevalent in neoplasia. Grimm *et al.* [@b91-conc17-1-70] reported that delivery of adeno-associated virus ([aav]{.smallcaps})--mediated recombinant pre-mi[rna]{.smallcaps}s causes death in mice from severe liver cytotoxicity. Details of the immunogenic and cytotoxic effects of let-7 therefore need to be explored so that such side effects can be minimized in an effective treatment strategy. Similarly, we proposed that let-7 may be involved in an as-yet-unknown regulatory network of mi[rna]{.smallcaps}s that resembles the gene regulatory network involving transcription factors. Therefore, anti-mi[rna]{.smallcaps} oligo-based knockdown of let-7 inhibitory mi[rna]{.smallcaps}s is not currently possible.

### 2.5.2. Limitations in Delivery Methods and Systems

Lack of an appropriate, safe, and effective delivery method for let-7 is another drawback of possible therapy. Biological vectors such as [aav]{.smallcaps} and lentivirus may be used for targeted delivery [@b92-conc17-1-70], but standardization of the method is required to prevent non-targeted site introduction. Also, brain-specific mi[rna]{.smallcaps} delivery is not yet successful [@b93-conc17-1-70], and effective neuron-specific delivery methods have to be developed to tackle brain and neuronal tumours. As discussed earlier, [aav]{.smallcaps}- and lentivirus-mediated delivery of let-7 in a mouse model of lung cancer [@b52-conc17-1-70],[@b90-conc17-1-70] was found to be inefficient in pre-existing tumours because of the resistance to let-7 developed by the tumour over time [@b52-conc17-1-70]. A strategy for let-7--mediated therapy for pre-existing tumours therefore also has to be developed.

2.6. Strategies to Overcome the Limitations
-------------------------------------------

The optimal or normal level of let-7 may be restored in cancer cells either by administering exogenous let-7 *in situ* with a vector overexpressing let-7, or by repressing let-7 repressors. Recent mi[rna]{.smallcaps} technologies are, in general, designed to use complementary or chemically modified single-stranded [rna]{.smallcaps} analogs (or both) to repress the specific mi[rna]{.smallcaps}s responsible for a given disease or cancer. These analogs, including [aso]{.smallcaps}s (antisense oligonucleotides), [amo]{.smallcaps}s (anti-mi[rna aso]{.smallcaps}s called "antagomirs"), locked nucleic acids, and antisense-technology-based small interfering [rna]{.smallcaps}s, are widely and effectively used in regulation of mi[rna]{.smallcaps} expression [@b92-conc17-1-70],[@b94-conc17-1-70]--[@b99-conc17-1-70]. But direct information is not available on the mi[rna]{.smallcaps}s that regulate let-7 expression; this aspect limits the scope for such a strategy. Instead, technologies are required that can effectively upregulate let-7 expression. Hence, either vector-mediated overexpression of let-7 or transient transfection of double-stranded let-7 will be the choice.

Introduction of double-stranded let-7 duplex may produce mature let-7, equivalent to the endogenous version, during Dicer processing, potentially rescuing a downregulated let-7 level. This strategy has already been successfully used [@b83-conc17-1-70]. Vectors containing pre--let-7--like synthetic short hairpin [rna]{.smallcaps}s, driven by highly inducible Pol [iii]{.smallcaps} promoters such as H1 and U6 [@b100-conc17-1-70],[@b101-conc17-1-70] may provide high expression of let-7 from predefined transcription start and termination sites [@b102-conc17-1-70]. But instead of designing artificial hairpins, direct cloning of the entire natural pri--let-7 hairpin with flanking sequences into the expression vector may be a better approach--- assuming that natural pre--let-7 will be a better substrate for generating mature let-7 during Dicer processing [@b103-conc17-1-70]--[@b107-conc17-1-70]. A pri-[mir]{.smallcaps}--Pol [ii]{.smallcaps} transgene system has been successfully used to overexpress [mir]{.smallcaps}155 [@b104-conc17-1-70], [mir]{.smallcaps}30 [@b108-conc17-1-70], and [mir]{.smallcaps}122 [@b109-conc17-1-70]. This system was also found useful in expressing multiple mi[rna]{.smallcaps}s from a single transcript [@b104-conc17-1-70] and can therefore be adopted for let-7 expression too.

High-density lipoprotein conjugated si[rna]{.smallcaps} has been reported to increase delivery efficacy in certain specific organs such as liver, gut, kidney, and steroid secreting organs [@b110-conc17-1-70]. A similar approach may therefore have the possibility to be effective in let-7 delivery as well. But the synthesis and purification of therapeutic-grade let-7 is difficult. A nanoparticle-based delivery system may prove beneficial.

Other delivery methods that have been found promising in both *in vitro* and *in vivo* conditions include lentivirus-mediated pre--let-7 oligonucleotides [@b36-conc17-1-70], adenovirus-mediated delivery of hairpin sequences of mature let-7 [@b90-conc17-1-70], cationic liposome--mediated delivery of pre--let-7 [@b40-conc17-1-70], and electroporation of synthetic let-7 [@b90-conc17-1-70]. Although such methods are at the bench level, they might be translated into therapeutic approaches in the near future.

2.7. Current Industry Status of Let-7 Therapy
---------------------------------------------

Because of its potential as a cancer therapeutic, let-7 has been filed for patent protection (Australia: 2007/333109 A1; United States: 20090163430). While diagnostic companies are developing let-7--based tests for various diseases, including several cancers, pharma giants are working toward development of effective delivery systems. But let-7 restoration methods are not yet satisfactory. Asuragen ([www.asuragen.com](www.asuragen.com)), the [rna]{.smallcaps}-based therapeutic and diagnostics major with a core focus on mi[rna]{.smallcaps} through its subsidiary Mirna Therapeutics ([www.mirnatherapeutics.com](www.mirnatherapeutics.com)), is developing mi[rna]{.smallcaps}-based diagnostics and therapeutics for non-small-cell lung cancer, metastatic prostate cancer, and acute myeloid leukemia---all currently in preclinical trials. For lung cancer and acute myeloid leukemia, their main focus is let-7. Similarly, Regulus Therapeutics LLC ([www.regulusrx.com](www.regulusrx.com)) is using more than 60 mi[rna]{.smallcaps}s, including let-7, to develop mi[rna]{.smallcaps} therapeutics to treat several diseases (including cancers). Their main focus is on delivery systems and enhancement of treatment efficacy.

3.. SUMMARY
===========

Let-7 exerts its tumour suppressor and antiproliferative activities by repressing several oncogenes and by regulating key regulators of the cell cycle, cell differentiation, and apoptotic pathways. Downregulation of let-7 is a common phenomenon in several cancers, and restoration of normal let-7 expression has been found to prevent cancer growth. As a result, let-7 is a molecular marker in certain cancers and a potential therapeutic in cancer therapy. However, efficient delivery strategies have to be developed if this molecule is to be used as a therapeutic *in vivo.* Use of viral vectors, artificial virus-like particles, and nano materials may be a promising way to realize this goal, but optimization is needed. Also, a better understanding of let-7 biology and its regulatory networks is required to exploit the curative benefits of let-7 and to reduce off-target side effects.
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![The most-accepted model of micro[rna]{.smallcaps} (mi[rna]{.smallcaps}) biogenesis and its mechanism of action. For detail, see text. [rna]{.smallcaps} Pol [ii]{.smallcaps} = [rna]{.smallcaps} polymerase [ii]{.smallcaps}; Pri-mi[rna]{.smallcaps} = primary transcripts of mi[rna]{.smallcaps}; DGCR8 = DiGeorge syndrome critical region gene 8; Drosha = class 2 [rna]{.smallcaps}se [iii]{.smallcaps} enzyme; XPO5 = exportin 5; Dicer = formal symbol DICER1 (dicer 1, ribonuclease type [iii]{.smallcaps}); TRBP = now labelled TARBP2P \[[tar]{.smallcaps} ([hiv]{.smallcaps}-1) [rna]{.smallcaps} binding protein 2 pseudogene\]; Ago1--4 = Argonaute-1 to -4 \[symbol EIF2C1, 2, 3, 4 (eukaryotic translation initiation factor 2C, 1--4)\]; [rnp]{.smallcaps} = ribonucleoprotein; m[rna]{.smallcaps} = messenger [rna]{.smallcaps}.](conc17-1-70f1){#f1-conc17-1-70}

![Regulatory circuits of micro[rna]{.smallcaps} (mi[rna]{.smallcaps}) let-7. The loop consists of pluripotency promoting factors {LIN28 \[lin-28 homolog (*Caenorhabditis elegans*)\], OCT4 \[now labelled POU5F1 ([pou]{.smallcaps} class 5 homeobox 1)\], SOX2 \[[sry]{.smallcaps} (sex determining region Y)--box 2\], NANOG \[Nanog homeobox\], and TCL3 \[now labelled TLX1 (T-cell leukemia homeobox 1)\]}, oncofetal genes \[HMGA2 (high mobility group [at]{.smallcaps}--hook 2) and [imp]{.smallcaps}s (insulin-like growth factor 2 m[rna]{.smallcaps}-binding proteins)\], and oncogene MYC. For detail, see text. Pri-let 7 = primary transcripts of let-7; LIN28B = lin-28 homolog B (*C. elegans*).](conc17-1-70f2){#f2-conc17-1-70}

![Let-7 targets various key components of mitogenic and tumorigenic pathways to exert its tumour suppressor activity. Pathways include cell cycle, cell division, cell proliferation, [dna]{.smallcaps} replication, angiogenesis, and apoptosis. PLAGL1, 2 = pleomorphic adenoma gene-like 1, 2; CKS1B = [cdc]{.smallcaps}28 protein kinase regulatory subunit 1B; SKP2 = S-phase kinase-associated protein 2 (p45); [fgf]{.smallcaps}, [fgfr]{.smallcaps} = fibroblast growth factor and fibroblast growth factor receptor; [igf]{.smallcaps} = insulin-like growth factor; [il]{.smallcaps}-[s]{.smallcaps} = interleukin S; [tgfb]{.smallcaps} = transforming growth factor β; GRB2 = growth factor receptor-bound protein 2; [mapk]{.smallcaps} = mitogen-activated protein kinase; CYP19A1 = cytochrome P450, family 19, subfamily A, polypeptide 1; ESR1 = estrogen receptor 1; MMP2, 8 = matrix metallopeptidases 2, 8; ITGB3 = integrin β3; ANG = angiogenin; RRM1, 2 = ribonucleotide reductases M1 and M2; CDC6 = cell division cycle 6 homolog (*Saccharomyces cerevisiae*); ORC1L = origin recognition complex, subunit 1-like (yeast); MCM2 = minichromosome maintenance complex component 2; RFC2--5 = replication factor C (activator 1) 2--5; GMNN = geminin, [dna]{.smallcaps} replication inhibitor; E2F5, 6, 8 = [e]{.smallcaps}2[f]{.smallcaps} transcription factors 5, 6, 8; CDK8 = cyclin-dependent kinase 8; CDC16 = cell division cycle 16 homolog (*S. cerevisiae*); AURKA = aurora kinase A; CDC25A = cell division cycle 25 homolog A (*Schizosaccharomyces pombe*); CCNA2 = cyclin A2; CDC20, 23 = cell division cycle 20 and 23 homologs (*S. cerevisiae*); CDCA1 = (now labelled NUF2) NDC80 kinetochore complex component, homolog (*S. cerevisiae*); CHEK1 = [chk]{.smallcaps}1 checkpoint homolog (*S. pombe*); BUB1, 1B = budding uninhibited by benzimidazoles 1 and 1 β homologs (yeast); CCNB1, D1, D2, E2, F, J = cyclins B1, D1, D2, E2, F, J; CDC2 = cell division cycle 2, G1 to S and G2 to M; CDK2, 4, 6 = cyclin-dependent kinases 2, 4, 6; m[rna]{.smallcaps} = messenger [rna]{.smallcaps}.](conc17-1-70f3){#f3-conc17-1-70}

###### 

Deregulation of micro[rna]{.smallcaps} let-7 family members in various cancers

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cancers                                                                Micro[rna]{.smallcaps} let-7 family members      References
  ---------------------------------------------------------------------- ------------------------------------------------ -----------------------------------------------
  Cancers that exhibit downregulation of specific let-7 family members                                                    

   Acute lymphoblastic leukemia                                          let-7b                                           Mi *et al.,* 2007 [@b33-conc17-1-70]

   Bladder cancer                                                        let-7b, let-7d, let-7e, let-7f                   Nam *et al.,* 2008 [@b34-conc17-1-70]

   Breast cancer                                                         let-7, let-7a                                    Sempere *et al.,* 2007 [@b35-conc17-1-70]\
                                                                                                                          Yu *et al.,* 2007 [@b36-conc17-1-70]

   Bronchioloalveolar cancer                                             let-7                                            Inamura *et al.,* 2007 [@b37-conc17-1-70]

   Burkitt lymphoma                                                      let-7a                                           Sampson *et al.,* 2007 [@b38-conc17-1-70]

   Colon cancer                                                          let-7                                            Michael *et al.,* 2003 [@b39-conc17-1-70]\
                                                                                                                          Akao *et al.,* 2006 [@b40-conc17-1-70]\
                                                                                                                          Fang *et al.,* 2007 [@b41-conc17-1-70]

   Gastric cancer                                                        let-7                                            Zhang *et al.,* 2007 [@b42-conc17-1-70]\
                                                                                                                          Motoyama *et al.,* 2008 [@b43-conc17-1-70]

   Hepatocellular cancer                                                 let-7                                            Johnson *et al.,* 2007 [@b44-conc17-1-70]

   Kidney cancer                                                         let-7a, let-7c, let-7d, let-7e, let-7f, let-7g   Nam *et al.,* 2008 [@b34-conc17-1-70]

   Lung cancer                                                           let-7                                            Johnson *et al.,* 2007 [@b44-conc17-1-70]\
                                                                                                                          Takamizawa *et al.,* 2004 [@b45-conc17-1-70]\
                                                                                                                          Johnson *et al.,* 2005 [@b46-conc17-1-70]

   Malignant melanoma                                                    let-7b                                           Schultz *et al.,* 2008 [@b47-conc17-1-70]

   Ovarian cancer                                                        let-7a-3                                         Lu *et al.,* 2007 [@b48-conc17-1-70]

   Pancreatic cancer                                                     let-7                                            Jérôme *et al.,* 2007 [@b49-conc17-1-70]

   Prostate cancer                                                       let-7c                                           Jiang *et al.,* 2005 [@b50-conc17-1-70]

  Cancers that exhibit upregulation of specific let-7 family members                                                      

   Acute myeloid leukemia                                                let-7                                            Garzon *et al.,* 2008 [@b51-conc17-1-70]

   Breast cancer                                                         let-7b                                           Nam *et al.,* 2008 [@b34-conc17-1-70]

   Colon cancer                                                          let-7a, let-7g                                   Nam *et al.,* 2008 [@b34-conc17-1-70]

   Lung cancer                                                           let-7a                                           Nam *et al.,* 2008 [@b34-conc17-1-70]

   Retinoblastoma                                                        let-7a, let-7b, let-7c                           Nam *et al.,* 2008 [@b34-conc17-1-70]

   Uterine cancer                                                        let-7i                                           Nam *et al.,* 2008 [@b34-conc17-1-70]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Micro[rna]{.smallcaps} let-7 targets in various cancers

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cancer                  Micro[rna]{.smallcaps} let-7   Model used                                                                                                                                                                                                                                                                   References                                             
  ----------------------- ------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- -------------------------- --------------------------------------------
  Breast cancer           let-7 ↓                        *ANG; CCND1, 2; CDC25A; CDK4, 6;CYP19A1*; [dna]{.smallcaps} polymerases; *E2F5, 6; ESR1, 2; FGF11*; [fgfr]{.smallcaps}; *GRB2; HMGB2; IGF1, 1R; IL6; ITGB3; MAPK4, 6; MMP2; MMP8; MYC; ras; RB1; SKP2; TGFB1, BR1; TP53*                                                     Transcription               *In silico*                Barh *et al.,* 2008 [@b82-conc17-1-70]

                          let-7 ↓                        *HMGA2,* H*-ras*                                                                                                                                                                                                                                                             Transcription               Cell line, mouse model     Sempere *et al.,* 2007 [@b35-conc17-1-70]\
                                                                                                                                                                                                                                                                                                                                                                                             Yu *et al.,* 2h007 [@b36-conc17-1-70]

  Burkitt lymphoma        let-7a ↓                       *MYC*                                                                                                                                                                                                                                                                        Transcription/translation   Cell line                  Sampson *et al.,* 2007 [@b38-conc17-1-70]

  Colon cancer            let-7 ↓                        *ras*, *MYC*                                                                                                                                                                                                                                                                 Translation                 Cell line                  Akao *et al.,* 2006 [@b40-conc17-1-70]

  Hepatocellular cancer   let-7 ↓                        *AURKA; BRCA1, 2; BUB1; CCNA2, B1, E2, F, J; CDC2, 6, 20, 23, 25A, 34, 45L; NUF2; CBX2; CDCA2, 3, 4, 5, 7, 8; CDK8; CHEK1; CKS1B; DBF4; DICER1; E2F5, 6, 8;FANCD2; GMNN; CDT1; HMGA2; LIN28B; MAD2L1; NRAS; ORC1L; PLAGL1, 2; RRM1, 2; SKP2; SOX9; ARUKB* (formerly STK12)   Transcription               Cell line                  Johnson *et al.,* 2007 [@b44-conc17-1-70]

  Lung cancer             let-7 ↓                        *MYC*, *ras*                                                                                                                                                                                                                                                                 Transcription/translation   Cell line                  Johnson *et al.,* 2005 [@b46-conc17-1-70]\
                                                                                                                                                                                                                                                                                                                                                                                             Kumar *et al.,* 2008 [@b52-conc17-1-70]

                          let-7 ↓                        *AURKA; CCNA2; CDC34; CDK8; DBF4; DICER1; E2F5; GMNN; HMGA2; LIN28B; NRAS; PLAGL1, 2; ARUKB* (formerly STK12)                                                                                                                                                                Transcription               A549 lung cancer cells     Johnson *et al.,* 2007 [@b44-conc17-1-70]

                          let-7 ↓                        *HMGA2*                                                                                                                                                                                                                                                                      Transcription               Cell line                  Kumar *et al.,* 2008 [@b52-conc17-1-70]\
                                                                                                                                                                                                                                                                                                                                                                                             Lee and Dutta, 2007 [@b83-conc17-1-70]

  Malignant melanoma      let-7b ↓                       *CDK4*; cyclins A, D1, D3                                                                                                                                                                                                                                                    Translation                 Cell line                  Schultz *et al.,* 2008 [@b47-conc17-1-70]

  Uterine leiomyoma       let-7 ↓                        *HMGA2*                                                                                                                                                                                                                                                                      Transcription               Tumour sample, cell line   Peng *et al.,* 2008 [@b84-conc17-1-70]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[fgfr]{.smallcaps} = fibroblast growth factor receptor; ↓ = downregulation.
